|
|
|
|
|
by HarryHirsch
3076 days ago
|
|
They could have used trade secrets. Konrad Zuse tells the story that back then, optical equipment manufacturers used to contract him for computations. Instead of rooms full of mechanical calculators operated by humans (the original "computers") they would supply his company with data and algorithms and he would reply back with results. Apparently, there were design reasons why for electronic calculations a different mathematical formulation was more efficient. The competing manufacturers would discover this fact one by one, and Zuse was worried that someone may question his integriry, thinking he was the source of the leak. But no one did. Michael Hanack (the materials chemist) used a different strategy: he would not patent anything so his inventions could be used my any market participant, and he would consult for all of them. On the other hand, everyone is looking forward to the day the aptamer patent runs out. Uptake is limited (and you'd think that CRISPR/CAS9 has the same problem) because of unreasonableness (in case of CRISPR uncertainty) around licensing. |
|
> Michael Hanack (the materials chemist) used a different strategy: he would not patent anything so his inventions could be used my any market participant, and he would consult for all of them.
That won't work if the invention is easily copied. Chemistry is tricky and there's probably plenty of money to be made in consulting in it. A lot of industries aren't like that.